Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Novo Nordisk is planning a new Phase III trial for CagriSema ... the weight loss seen after 68 weeks might not have been the ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was ... Among this high-dose group, weight loss had not started to plateau at the 68-week timepoint ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is planning a new Phase III trial for CagriSema ... dose subgroup by the end of the follow-up, weight loss had not started to plateau. "This suggests that additional weight loss ...